简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:The settlement stems from alleged violations of FINRA rules regarding conflicts of interest involving research analysts. According to these rules, firms must have policies in place to prevent analysts from trading securities in a manner inconsistent with their published ratings, and must disclose any financial interests analysts may have in covered companies.
The settlement stems from alleged violations of FINRA rules regarding conflicts of interest involving research analysts. According to these rules, firms must have policies in place to prevent analysts from trading securities in a manner inconsistent with their published ratings, and must disclose any financial interests analysts may have in covered companies.
Between January 2016 and August 2019, Barclays purportedly failed to establish and maintain a supervisory system, including written procedures, to comply with these rules. Specifically, the firm neglected to adequately monitor its research analysts' managed brokerage accounts for compliance with trading restrictions or to ascertain if they held securities in covered companies. This failure resulted in the non-disclosure of analyst-held securities in 99 equity research reports, as well as the oversight of three instances where an analyst's external account manager traded against their published recommendations.
These actions led to violations of several FINRA rules, including 2241(b)(2)(J), 224l(c)(4)(A), 3110(a) and (b)(1), and 2010. Furthermore, Barclays' written supervisory procedures lacked a process to review securities transactions in analysts' external accounts for potential securities law violations, such as market manipulation and insider trading, thus contravening FINRA Rules 3110(d) and 2010.
Additionally, from April 2021 to March 2022, Barclays allegedly failed to gather data for certain clients of its affiliates to determine if disclosure of conflicts of interest was necessary in research reports. Consequently, the firm omitted disclosures in at least 803 reports covering 22 issuers, indicating affiliations and compensation received from issuers within the preceding 12 months, in violation of FINRA Rules 2241(c)(4)(D) and 2010.
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.
Discover how MultiBank Group, a global leader in financial derivatives, secured three prestigious awards at Traders Fair Hong Kong 2024, highlighting its innovative trading solutions and industry excellence.
Discover how CySEC resolved compliance issues with Charlgate Ltd, the operator of Fxview, through a €50,000 settlement. Explore the investigation, regulatory measures, and CySEC's new website designed for improved accessibility and transparency.
Discover TradingView's DEX Screener, a powerful tool for analyzing decentralized exchange trading pairs. Access metrics like liquidity, trading volume, and FDV to make smarter, data-driven trading decisions.
PT. Doo Financial Futures, a subsidiary of the global financial services brand Doo Group, has secured regulatory approval from Indonesia’s Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI).